Press Releases

2007
09/25/2007 VaxInnate Initiates Phase I Clinical Study of M2e Universal Influenza Vaccine Company’s First Clinical Trial Studies Vaccine Based on New Vaccine Technology 07/23/2007 VaxInnate Awarded NIH Funding for Collaborative Dengue Fever Vaccine Development Award based on TLR technology platform’s application in developing vaccines for Flavivirus and other infectious diseases 06/06/2007 Two Significant Hires Round-Out VaxInnate’s Core Management Team Newly appointed CFO and COO bring extensive experience to support and further the company’s vaccine development programs 03/23/2007 David Taylor, MD, Joins VaxInnate as Chief Medical Officer Dr. Taylor's Extensive Experience in Infectious Disease and Vaccine Research Will Support Advancement of Avian and Seasonal Influenza, Malaria Vaccines		Media Inquiries Krystle Ficco Feinstein Kean Healthcare 617-761-6702 Krystle.Ficco@fkhealth.com
2006 12/01/2006 UTMB receives $9.5M grant from Gates foundation help study and develop VaxInnate flu vaccine. VaxInnate is a UTMB-selected subcontractor on the grant. 11/30/2006 U.S. Congressman Rush Holt Visits VaxInnate to Announce Govt. Funding for Collaborative Malaria Vaccine Development Defense Appropriations Act awards $1million to VaxInnate for vaccine research 10/25/2006 VaxInnate Secures $40 Million Series C Financing Funds will support commercial development of novel human and avian flu vaccines 10/23/2006 VaxInnate Reports Promising Results for Novel Influenza Vaccine Candidates Early testing demonstrates company’s innovative technology yields strong immunogenicity 2004 10/11/2004 VaxInnate Corporation Staff Additions and New Jersey Facility 10/11/2004 VaxInnate Corporation Receives Contract and Grant from the Department of Health and Human Services 03/11/2004 VaxInnate Corporation Raises $23.1 Million in Series B Financing